Enovix Corporation (ENVX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ENVX SEC filings page.
Enovix Corporation (ENVX) reported $35.9M in revenue over the twelve months to Jul 5, 2026, up 34.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Enovix is improving direct production economics, but development spending and debt still dominate how the business is financed.
Gross margin turned from-8.9% in FY2024 to19.2% in FY2025, indicating that sales began contributing after direct costs. Yet FY2025 still produced a net loss of$156.7M while R&D was 3.5x revenue, so the constraint shifted from direct production economics to absorbing development spending.
Operating cash flow moved from
Total liabilities rose from
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Enovix Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Enovix Corporation held $618.9M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $95.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Enovix Corporation scores 73/100 among other emerging companies.
Enovix Corporation had 217M shares outstanding at the end of fiscal year 2025, against 191M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Enovix Corporation scores 43/100 among other emerging companies.
Enovix Corporation spent $110.3M on research and development in fiscal year 2025, which was 52.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Enovix Corporation scores 79/100 among other emerging companies.
Enovix Corporation reported revenue of $31.8M in fiscal year 2025, against $23.1M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Enovix Corporation scores 86/100 among other emerging companies.
Enovix Corporation's operations used $95.3M of cash in fiscal year 2025, against $108.6M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Enovix Corporation scores 50/100 among other emerging companies.
Enovix Corporation's cash, cash equivalents and investments came to $618.9M at the end of fiscal year 2025, against $605.0M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Enovix Corporation scores 59/100 among other emerging companies.
Enovix Corporation scores -1.00, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($539.8M) relative to total liabilities ($605.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Enovix Corporation passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Enovix Corporation reported a net loss of $156.7M while operations used $95.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Enovix Corporation reported an operating loss of $177.3M against $12.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Enovix Corporation generated $9.0M in revenue in Q3 2026. This represents an increase of 12.9% from the same quarter a year earlier. Against the prior quarter it is up 18.7%.
Enovix Corporation's EBITDA was -$33.3M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 15.3% from the same quarter a year earlier. Against the prior quarter it is up 3.7%.
Enovix Corporation reported -$43.1M in net income in Q3 2026. This represents an increase of 19.8% from the same quarter a year earlier. Against the prior quarter it is down 12.6%.
Enovix Corporation earned -$0.20 per diluted share (EPS) in Q3 2026. This represents an increase of 25.9% from the same quarter a year earlier. Against the prior quarter it is down 11.1%.
Cash & Balance Sheet
Enovix Corporation recorded an outflow of $31.4M in free cash flow in Q3 2026, representing a cash shortfall after capex. This represents a decrease of 10.2% from the same quarter a year earlier. Against the prior quarter it is up 13.5%.
Enovix Corporation held $33.7M in cash against $521.0M in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Enovix Corporation's gross margin was 14.4% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 3.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 6.0 percentage points.
Enovix Corporation's ROE was -20.5% in Q3 2026, measuring profit generated per dollar of shareholder equity. This is down 2.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.6 percentage points.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Enovix Corporation invested $24.4M in research and development in Q3 2026. This represents a decrease of 13.3% from the same quarter a year earlier. Against the prior quarter it is down 7.9%.
Enovix Corporation invested $9.6M in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 223.7% from the same quarter a year earlier. Against the prior quarter it is up 198.9%.
Not reported for Q3 2026.
ENVX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.0M+12.9% | $7.6M+1.8% | $11.3M+15.9% | $8.0M+85.1% | $7.5M+98.2% | $5.1M-3.3% | $9.7M+4758.5% | $4.3M+10178.6% |
| Cost of Revenue | $7.7M+17.2% | $6.0M+9.4% | $8.8M+1.1% | $6.6M+32.9% | $5.5M+24.9% | $4.8M-31.6% | $8.7M-48.5% | $5.0M-65.2% |
| Gross Profit | $1.3M-7.1% | $1.6M-20.1% | $2.5M+137.7% | $1.4M+318.2% | $1.9M+396.5% | $261K+114.5% | $1.1M+106.3% | -$642K+95.5% |
| R&D Expenses | $24.4M-13.3% | $26.5M-5.8% | $28.1M+25.1% | $28.2M+16.4% | $28.1M-3.2% | $25.9M-46.9% | $22.4M+66.1% | $24.2M+46.3% |
| SG&A Expenses | $20.2M-0.2% | $18.9M+7.9% | $18.4M+40.2% | $20.2M-2.7% | $17.5M-16.1% | $16.9M-13.6% | $13.1M-23.8% | $20.7M+24.3% |
| Operating Income | -$43.3M+7.8% | -$43.9M-0.4% | -$44.0M-27.4% | -$47.0M+4.7% | -$43.7M+50.7% | -$42.6M+39.3% | -$34.5M+31.5% | -$49.3M+5.0% |
| EBITDA | -$33.3M+15.3% | -$34.5M+5.6% | -$32.2M-24.9% | -$39.3M+9.5% | -$36.6M+56.2% | -$34.1M+24.5% | -$25.8M+44.9% | -$43.4M+10.2% |
| Interest Expense | $6.5M+156.5% | $7.0M+311.0% | $6.4M+272.6% | $2.5M+48.0% | $1.7M+0.8% | $1.7M+3.4% | $1.7M+10.5% | $1.7M+35.2% |
| Income Tax | -$441K-4.5% | -$129K+85.0% | $133K-88.5% | -$422K-119.2% | -$861K+81.2% | -$162K-6.6% | $1.2M | $2.2M |
| Net Income | -$43.1M+19.8% | -$38.3M+14.1% | -$35.0M+6.6% | -$53.7M-138.3% | -$44.5M+61.6% | -$23.5M+49.3% | -$37.5M-131.5% | -$22.5M+65.0% |
| EPS (Basic) | -$0.20+23.1% | -$0.18+18.2% | -$0.16+11.1% | -$0.26-116.7% | -$0.22+65.1% | -$0.12+57.1% | -$0.18-80.0% | -$0.12+70.7% |
| EPS (Diluted) | -$0.20+25.9% | -$0.18+18.2% | -$0.16+11.1% | -$0.27 | -$0.22+65.1% | -$0.12+57.1% | -$0.18 | -$0.28 |
| Diluted Shares (Avg) | 219M+5.7% | 217M+6.1% | N/A | 207M | 205M+11.8% | 203M+20.9% | N/A | 188M |
ENVX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $799.6M-12.5% | $833.9M+77.8% | $879.0M+66.7% | $913.7M+103.9% | $469.1M-4.1% | $499.0M-1.9% | $527.2M+1.4% | $448.0M-16.9% |
| Current Assets | $505.7M-14.1% | $558.5M+144.6% | $542.2M+83.8% | $588.6M+162.8% | $228.3M-15.4% | $270.2M-2.8% | $295.0M-21.5% | $224.0M-45.9% |
| Cash & Equivalents | $33.7M-89.9% | $88.8M-34.7% | $106.0M-61.1% | $335.5M+67.0% | $136.0M-42.2% | $189.9M-14.5% | $272.9M+0.8% | $200.9M-41.5% |
| Short-Term Investments | $442.0M+97.9% | $440.0M+552.5% | $406.0M | $223.3M | $67.4M+354.8% | $58.3M+44.8% | $0-100.0% | $0-100.0% |
| Inventory | $17.5M+15.1% | $16.5M+22.9% | $13.6M+77.7% | $15.2M+59.2% | $13.4M+40.8% | $10.5M+60.4% | $7.7M+3464.7% | $9.6M+1101.5% |
| Accounts Receivable | $3.1M-33.1% | $3.9M-7.1% | $4.4M-3.2% | $4.6M+142.3% | $4.2M+154.9% | $2.9M+67.7% | $4.6M+456500.0% | $1.9M+4450.0% |
| Long-Term Investments | $74.4M-16.8% | $52.1M | $106.8M | $89.5M | $0 | $0 | $0 | $0 |
| Goodwill | $12.2M0.0% | $12.2M0.0% | $12.2M0.0% | $12.2M0.0% | $12.2M0.0% | $12.2M0.0% | $12.2M | $12.2M |
| Total Liabilities | $587.6M-4.7% | $591.2M+125.2% | $605.0M+117.8% | $616.6M+122.0% | $262.5M-16.9% | $261.3M-5.6% | $277.8M+3.9% | $277.8M-4.8% |
| Current Liabilities | $52.1M-14.0% | $50.9M-2.6% | $65.0M+21.1% | $60.6M+1.9% | $52.3M-23.0% | $57.8M+1.6% | $53.7M+21.7% | $59.5M+59.1% |
| Non-Current Liabilities | $535.5M-3.7% | $540.3M+157.0% | $539.9M+141.0% | $556.0M+154.7% | $210.2M-15.3% | $203.5M-7.5% | $224.1M+0.3% | $218.3M-14.1% |
| Long-Term Debt | $521.0M+0.5% | $520.2M+207.0% | $519.3M+205.8% | $518.3M+207.2% | $169.4M+0.6% | $169.2M+0.5% | $169.8M+1.6% | $168.7M+1.2% |
| Total Equity | $209.9M-28.7% | $240.7M+18.1% | $271.2M+9.9% | $294.3M+75.6% | $203.7M+19.6% | $235.1M+2.6% | $246.7M-2.3% | $167.6M-32.2% |
| Retained Earnings | -$1.1B-12.3% | -$1.0B-14.3% | -$977.8M-19.1% | -$942.8M-20.3% | -$889.1M-16.8% | -$844.6M-30.9% | -$821.1M-52.4% | -$783.6M-49.9% |
ENVX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$21.8M+14.7% | -$33.1M-27.9% | -$27.0M-69.2% | -$25.5M+16.8% | -$25.9M+4.0% | -$16.9M+51.8% | -$16.0M+43.5% | -$30.7M-30.3% |
| Depreciation & Amortization | $10.0M+30.3% | $9.4M+30.5% | $8.4M+11.8% | $7.7M+30.9% | $7.2M+33.9% | $8.4M-66.2% | $7.5M+110.3% | $5.9M+67.0% |
| Stock-Based Compensation | $13.0M+10.1% | $11.8M-16.7% | N/A | $11.8M-29.7% | $14.1M-25.8% | $12.0M-5.8% | N/A | $16.8M+11.9% |
| Capital Expenditures | $9.6M+223.7% | $3.2M-59.6% | $1.0M-93.8% | $3.0M-84.8% | $8.0M-68.4% | $6.3M-58.4% | $16.4M-5.2% | $19.5M+53.9% |
| Free Cash Flow | -$31.4M-10.2% | -$36.3M-7.3% | -$28.0M+13.3% | -$28.5M+43.2% | -$33.8M+35.1% | -$23.2M+53.8% | -$32.3M+29.0% | -$50.2M-38.5% |
| Investing Cash Flow | -$33.7M+86.4% | $18.3M+168.6% | -$199.1M-1116.9% | -$248.1M-5373.5% | -$26.7M-6680.8% | -$64.4M-436.9% | -$16.4M+67.6% | -$4.5M+94.2% |
| Financing Cash Flow | $466K-99.9% | -$2.5M-105.9% | -$3.3M-103.1% | $473.4M+54893.8% | -$1.2M-103.0% | -$1.5M-127.5% | $106.5M+1547.8% | -$864K-100.6% |
| Share Buybacks | N/A | N/A | $0 | $58.4M+5838400.0% | N/A | N/A | $0-100.0% | -$1K-75.0% |
Not reported in any period shown, so not listed: Dividends Paid.
ENVX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 14.4%-3.1pp | 20.4%-5.6pp | 22.2%+11.4pp | 17.5%+32.4pp | 26.0%+43.4pp | 5.1%+39.3pp | 10.8% | -14.9% |
| Operating Margin | -479.8% | -577.6% | -390.5% | -587.9% | -585.6% | -834.8% | -355.2% | -1141.2% |
| Net Margin | -477.2% | -503.4% | -310.6% | -672.3% | -596.3% | -461.2% | -385.6% | -522.0% |
| Return on Equity | -20.5%-2.3pp | -15.9%+5.9pp | -12.9%+2.3pp | -18.3%-4.8pp | -21.9%+46.2pp | -10.0%+10.2pp | -15.2%-8.8pp | -13.5%+12.6pp |
| Return on Assets | -5.4%+0.5pp | -4.6%+4.9pp | -4.0%+3.1pp | -5.9%-0.9pp | -9.5%+14.2pp | -4.7%+4.4pp | -7.1%-4.0pp | -5.0%+6.9pp |
| Current Ratio | 9.710.0x | 10.97+6.6x | 8.34+2.8x | 9.72+6.0x | 4.37+0.4x | 4.68-0.2x | 5.49-3.0x | 3.77-7.3x |
| Debt-to-Equity | 2.48+0.7x | 2.16+1.3x | 1.91+1.2x | 1.76+0.8x | 0.83-0.2x | 0.720.0x | 0.690.0x | 1.01+0.3x |
| Asset Turnover | 0.010.0x | 0.010.0x | 0.010.0x | 0.010.0x | 0.020.0x | 0.010.0x | 0.020.0x | 0.010.0x |
| FCF Margin | -348.0% | -477.5% | -248.6% | -356.7% | -453.0% | -454.7% | -332.6% | -1163.2% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Enovix Corporation ENVX | FY2025 | $31.8M | -$156.7M | N/A | $539.8M | 65/100 |
| Energizer Holdings, Inc ENR | FY2025 | $3.0B | $239.0M | 8.1% | $1.5B | 25/100 |
| Amprius Technologies, Inc. AMPX | FY2025 | $73.0M | -$44.0M | -60.3% | $1.4B | 53/100 |
| ADS-TEC ENERGY PLC ADSE | FY2023 | N/A | N/A | N/A | $726.3M | — |
| Eos Energy Enterprises, Inc. EOSE | FY2025 | $114.2M | -$969.6M | N/A | $917.7M | 43/100 |
| Preformed Line Products Co PLPC | FY2025 | $669.3M | $35.3M | 5.3% | $1.9B | 68/100 |
Where Enovix Corporation Ranks
Frequently Asked Questions
What is Enovix Corporation's annual revenue?
Enovix Corporation (ENVX) reported $31.8M in total revenue for fiscal year 2025. This represents a 37.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Enovix Corporation's revenue growing?
Enovix Corporation (ENVX) revenue grew by 37.9% year-over-year, from $23.1M to $31.8M in fiscal year 2025.
Is Enovix Corporation profitable?
No, Enovix Corporation (ENVX) reported a net income of -$156.7M in fiscal year 2025.
What is Enovix Corporation's EBITDA?
Enovix Corporation (ENVX) had EBITDA of -$142.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Enovix Corporation have?
As of fiscal year 2025, Enovix Corporation (ENVX) had $106.0M in cash and equivalents against $519.3M in long-term debt.
What is Enovix Corporation's gross margin?
Enovix Corporation (ENVX) had a gross margin of 19.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Enovix Corporation's return on equity (ROE)?
Enovix Corporation (ENVX) has a return on equity of -57.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Enovix Corporation's free cash flow?
Enovix Corporation (ENVX) recorded an outflow of $113.5M in free cash flow during fiscal year 2025. This represents a 38.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Enovix Corporation's operating cash flow?
Enovix Corporation (ENVX) recorded an outflow of $95.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Enovix Corporation's total assets?
Enovix Corporation (ENVX) had $879.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Enovix Corporation's capital expenditures?
Enovix Corporation (ENVX) invested $18.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Enovix Corporation spend on research and development?
Enovix Corporation (ENVX) invested $110.3M in research and development during fiscal year 2025.
What is Enovix Corporation's current ratio?
Enovix Corporation (ENVX) had a current ratio of 8.34 as of fiscal year 2025, which is generally considered healthy.
What is Enovix Corporation's debt-to-equity ratio?
Enovix Corporation (ENVX) had a debt-to-equity ratio of 1.91 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Enovix Corporation's return on assets (ROA)?
Enovix Corporation (ENVX) had a return on assets of -17.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Enovix Corporation's P/E ratio?
Enovix Corporation (ENVX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to July 5, 2026). The market capitalization is $539.8M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Enovix Corporation's price-to-sales ratio?
Enovix Corporation (ENVX) trades at 15.0x sales, its market capitalization divided by revenue of $35.9M revenue, trailing 12 months to July 5, 2026. The market capitalization is $539.8M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Enovix Corporation's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Enovix Corporation (ENVX) held $618.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $95.3M over that year. Dividing the one by the other, the reported balance equals about 78 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Enovix Corporation's Altman Z-Score?
Enovix Corporation (ENVX) has an Altman Z-Score of -1.00, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Enovix Corporation's Piotroski F-Score?
Enovix Corporation (ENVX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Enovix Corporation's earnings high quality?
Enovix Corporation (ENVX) reported a net loss of $156.7M while operations used $95.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Enovix Corporation cover its interest payments?
Enovix Corporation (ENVX) reported an operating loss of $177.3M against $12.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Enovix Corporation?
Enovix Corporation (ENVX) scores 65 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.